Skip to main content
Cytogen, Inc. logo

Cytogen, Inc. — Investor Relations & Filings

Ticker · 217330 ISIN · KR7217330000 KO Manufacturing
Open in API
Filings indexed 437 across all filing types
Latest filing 2020-04-27 Regulatory Filings
Country KR South Korea
Listing KO 217330

About Cytogen, Inc.

https://www.cytogenlab.com/

Cytogen, Inc. is a biotechnology company specializing in liquid biopsy platforms for precision oncology. The company has developed proprietary technology for the rapid isolation and analysis of viable Circulating Tumor Cells (CTCs) from whole blood. Its core offering, the SmartBiopsy Platform, utilizes a high-density microporous chip with microfluidics and nanotechnology to capture CTCs efficiently. This non-invasive diagnostic approach is designed to support early cancer detection, treatment monitoring, and the advancement of personalized medicine for cancer patients.

Recent filings

Filing Released Lang Actions
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (Cytogen) announcing a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결). It details the contract amount, the counterparty, the contract period, and the nature of the supply (multi-immune diagnostic automation platform). Since this is a specific corporate announcement regarding a business contract that does not fit into the other specialized categories like M&A or financial reports, it falls under the general regulatory filing category.
2020-04-27 Korean
사업보고서 (2019.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'CytoGen' (주식회사 싸이토젠) for the fiscal year ending December 31, 2019. It includes the independent auditor's report from Samil PricewaterhouseCoopers, the financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. This is a comprehensive financial audit document, not an earnings release or a simple announcement. FY 2019
2020-03-30 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, dividend decisions, director appointments, and business purpose changes. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-03-20 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options). It details the issuance of stock options to specific directors and employees, including the number of shares, exercise price, and vesting conditions. In the context of Korean financial regulations (DART system), this is a standard disclosure regarding capital changes and equity-based compensation. Since it does not fit into the specific categories of 'Director's Dealing' (which usually refers to trading existing shares) or 'Share Issue' (which refers to capital increases), and it is a specific regulatory disclosure of a corporate action, it falls under the 'Regulatory Filings' (RNS) category as the most appropriate fallback for miscellaneous corporate disclosures.
2020-03-20 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed under the Capital Markets Act in South Korea. This type of filing is used to report changes in significant share ownership (crossing thresholds) by major shareholders and their special related parties. According to the provided definitions, this corresponds to the 'Major Shareholding Notification' (MRQ) category.
2020-03-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Jeon Byung Hee) of Cytogen. This document details the acquisition of shares by an insider, which is a standard disclosure for director/executive dealings. In the provided classification schema, this falls under 'Director's Dealing' (DIRS).
2020-03-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.